New hope for hard-to-treat MDS: triple-drug combo tested in small trial
NCT ID NCT05564650
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study tests a new combination of three drugs (navitoclax, venetoclax, and decitabine) in about 6 adults with high-risk myelodysplastic syndrome (MDS) that came back or didn't respond to initial treatment. The goal is to find the safest dose and see if the combo can shrink or control the cancer. Participants take two oral pills and one IV drug, and the study monitors side effects, response, and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.